Journals / Turkish Journal of Gastroenterology / 2011 / Cilt: 22 - Sayı: 4

Non alkolik yağlı karaciğer hastalığının gelişiminde yeni bir risk faktörü: HLA kompleks genleri

A new risk factor for the development of non-alcoholic fatty liver disease: HLA complex genes

Pages
395–399
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusions: Our preliminary study suggests that human leukocyte antigen plays a role in the pathogenesis of non-alcoholic fatty liver disease; however, more studies are needed to clarify these data.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background/aims: Several studies have emphasized the role of genetic factors in susceptibility to non-alcoholic fatty liver disease.
📊
Key Findings & Data:Methods: Between January 2000 and January 2008, data of 655 donor candidates were examined from routinely performed abdominal ultrasonography and for aspartate aminotransferase, alanine aminotransferase, hepatitis B virus, hepatitis C virus, cytomegalovirus, human immunodeficiency virus, hepatic functions, and human leukocyte antigen class I and II antigens; data of 116 healthy candidates were also included in this study.
💡
Conclusion & Impact:Conclusions: Our preliminary study suggests that human leukocyte antigen plays a role in the pathogenesis of non-alcoholic fatty liver disease; however, more studies are needed to clarify these data.
🔬Design:Research Article
📍Scope:2000 Verileri
⚙️Variables:Domain Parameters

Abstract

Background/aims: Several studies have emphasized the role of genetic factors in susceptibility to non-alcoholic fatty liver disease. The aim of this study was to examine the possible influence of human leukocyte antigen in the development of non-alcoholic fatty liver disease. Methods: Between January 2000 and January 2008, data of 655 donor candidates were examined from routinely performed abdominal ultrasonography and for aspartate aminotransferase, alanine aminotransferase, hepatitis B virus, hepatitis C virus, cytomegalovirus, human immunodeficiency virus, hepatic functions, and human leukocyte antigen class I and II antigens; data of 116 healthy candidates were also included in this study. To reduce the influence of possible confounding factors, we excluded diseases known to be associated with non-alcoholic fatty liver disease like obesity, diabetes mellitus, coronary artery disease, hyperlipidemia, and metabolic syndrome. Non-alcoholic fatty liver disease was diagnosed in 66 individuals (33 male, median age: 53.8 [range, 32-77 years]) by means of ultrasonography data, and 50 individuals, whose ultrasonography data did not show hepatosteatosis, comprised the control group (20 male, median age: 44.6 [range, 26-71 years]). Results: Human leukocyte antigen-B65 (28.8% vs 0%, p<0.001) and DQ5 (40.7% vs 16.1%, p<0.05) were found to be expressed significantly more in non-alcoholic fatty liver disease compared with controls. Serum alanine aminotransferase (27.1 IU/L vs 20 IU/L, p<0.05) was significantly higher in the study group. Conclusions: Our preliminary study suggests that human leukocyte antigen plays a role in the pathogenesis of non-alcoholic fatty liver disease; however, more studies are needed to clarify these data.

Özet

Amaç: Çalışmalar genetik faktörlerin non alkolik yağlı karaciğer hastalığına yatkınlıkta etkili olduğunu göstermektedir. Bizim çalışmamızda non alkolik yağlı karaciğer hastalığı gelişiminde insan lökosit antijenlerinin muhtemel etkilerinin araştırılması amaçlanmıştır. Yöntem: Çalışmada ocak 2000 ve ocak 2008 tarihleri arasında hastanemize böbrek nakil verici adayı olarak başvuran kişilerin verileri kullanılmıştır. Her böbrek nakil verici adayına batın ultrasononografisi, HLA sınıf 1ve 2 antijenleri, karaciğer fonksiyon testleri, viral testler rutin olarak yapılmaktadır. Çalışmada 116 sağlıklı verici adayının bilgileri kullanılmıştır. Muhtemel genetik etkiyi engellemek için obezite, diyabetes mellitus, koroner arter hastalığı, hiperlipidemi ve metabolik sendrom gibi non alkolik yağlı karaciğer hastalığı ile yakın ilişki gösteren hastalıklar dışlanmıştır. Ultrasonografi ile 66 vericide non alkolik yağlı karaciğer hastalığı saptandı (33 erkek, ortalama yaş: 53,8 [yaş aralığı, 32-77]) ve ultrasonografisi normal 50 verici adayı kontrol grubu olarak alındı (20 erkek, ortalama yaş: 44,6 [yaş aralığı, 26-71]). Bulgular: Kontrol grubuyla karşılaştırıldığında non alkolik yağlı karaciğer hastalığı grubunda HLA B65 (28.8% vs 0%, p<0.001) ve DQ5 (40.7% vs 16.1%, p<0.05) istatistiksel olarak anlamlı yüksek bulunmuştur. Serum alanin aminotransferaz (27.1 ıu/l vs 20 ıu/l, p<0.05) non alkolik yağlı karaciğer hastalığı saptanan grupta anlamlı yüksek bulunmuştur. Sonuç: Ön çalışma niteliğinde olan bu çalışmada insan lökosit anitjenlerinin non alkolik yağlı karaciğer hastalığı patogenezinde rol alabileceği saptanılmıştır. Bu veriyi doğrulamak için ek çalışmalara gerek vardır.

🔖

Cite This Article

ÇELİKBİLEK, M., SELÇUK, H., YILMAZ, U. (2011). Non alkolik yağlı karaciğer hastalığının gelişiminde yeni bir risk faktörü: HLA kompleks genleri. Turkish Journal of Gastroenterology, Cilt: 22 - Sayı: 4, 395–399. https://ajindex.com/articles/409743

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (17)

  1. Chitturi S, Farrell G, George J. Non-alcoholic steatohepatitis in the Asia-Pacific region: future shock? J Gastroenterol Hepatol 2004; 19: 368-74
  2. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002; 346: 1221-31
  3. Ahishali E, Demir K, Ahishali B, et al. Electron microscopic findings in nonalcoholic fatty liver disease: is there any difference between hepatosteatosis and steatohepatitis? J Hepatology 2008; 48(Suppl 2): S341
  4. Ekstedt M, Franzén LE, Mathiesen UL, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006; 44: 865-73
  5. Sass DA, Chang P, Chopra KB. Nonalcoholic fatty liver disease: a clinical review. Dig Dis Sci 2005; 50: 171-80
  6. Marchesini G, Bugianesi E, Forlani G, et al. Non-alcoholic fatty liver, steatohepatitis and the metabolic syndrome. Hepatology 2003; 37: 917-23
  7. Musso G, Gambino R, Bo S, et al. Should nonalcoholic fatty liver disease be included in the definition of metabolic syndrome? A cross-sectional comparison with ATP III criteria in non-obese non-diabetic subjects. Diabetes Care 2008; 31: 562-8
  8. Lizardi-Cervera J, Chavez-Tapia NC, Pérez-Bautista O, et al. Association among C-reactive protein, fatty liver disease, and cardiovascular risk. Dig Dis Sci 2007; 52: 2375-9
  9. Wilfred de Alwis NM, Day CP. Non-alcoholic fatty liver disease: the mist gradually clears. J Hepatology 2008; 48: 104-12
  10. Struben VM, Hespenheide EE, Caldwell SH. Nonalcoholic steatohepatitis and cryptogenic cirrhosis within kindreds. Am J Med 2000; 108: 9-13
  11. Willner IR, Waters B, Patil SR, et al. Ninety patients with nonalcoholic steatohepatitis: insulin resistance, familial tendency, and severity of disease. Am J Gastroenterol 2001; 96: 2957-61
  12. Angulo P, Lindor KD. Non-alcoholic fatty liver disease. J Gastroenterol Hepatol 2002; 17(Suppl): 186-90
  13. Browning JD, Kumar KS, Saboorian MH, Thiele DL. Ethnic differences in the prevalence of cryptogenic cirrhosis. Am J Gastroenterol 2004; 99: 292-8
  14. Caldwell SH, Harris DM, Patrie JT, Hespenheide EE. Is NASH underdiagnosed among African Americans? Am J Gastroenterol 2002; 97: 1496-500
  15. HLA in Health and Disease. In: Lechler R, Warrens A, eds. London: Academic Press, 2000
  16. Quinn SF, Gosink BB. Characteristic sonographic signs of hepatic fatty infiltration. Am J Roentgenol 1985; 145: 753-5
  17. Joseph AE, Saverymuttu SH, al-Sam S, et al. Comparison of liver histology with ultrasonography in assessing diffuse parenchymal liver